Skip to main
IVVD

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd is a commercial-stage biopharmaceutical company focused on monoclonal antibody therapies for viral infectious diseases. Their lead mAb PEMGARDA, approved for pre-exposure prevention of COVID-19 in immunocompromised individuals, has shown superiority to mRNA vaccines. The company's next-generation mAb VYD2311, in P3 development, aims to protect a larger target population and is expected to read out by YE2026. With a solid clinical foundation and a promising pipeline, we view Invivyd as a strong investment opportunity, though it faces the usual risks of drug development.

Bears say

Invivyd is a biopharmaceutical company focused on developing monoclonal antibody therapies for viral infectious diseases, with its lead product, PEMGARDA, receiving emergency use authorization for COVID-19. However, only about 56% of treatment days have been recorded for their ongoing Phase 2 trial for Long COVID and COVID-19 post-vaccination syndrome, and management acknowledges the complexity of these conditions. The potential for high-risk, high-upside from SPEAR's positive results is overshadowed by its uncertain success and the company's reliance on one product for revenue.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.